person · Reporting owner
BCPE Perception GP, LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cerevel Therapeutics Holdings, Inc.
Report date August 01, 2024 · Filed August 05, 2024
Jointly reported with Bain Capital Investors LLC, BC Perception Holdings, LP, Bain Capital Fund XII, LP, Bain Capital Partners XII, LLC
Section 16 reporting ended · disclosed 2024-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 0 |
Reported balance
After 2024-08-01 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-08-01 · Disposition to issuer · Disposed 65,679,781 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash, without interest. F2: Represents shares of common stock held directly by BC Perception Holdings, LP ("BC Perception"). Bain Capital Fund XII, L.P. ("Fund XII") is the sole member of BCPE Perception GP, LLC ("Perception GP"), which is the general partner of BC Perception. Bain Capital Investors, LLC ("BCI") is the manager of Bain Capital Partners XII, LLC ("Partners XII" and, together with BCI, BC Perception, Fund XII and Perception GP, the "Bain Capital Entities"), which is the general partner of Fund XII. As a result, each of the Bain Capital Entities may be deemed to share voting and dispositive power with respect to the shares of common stock held by BC Perception. Each of the Bain Capital Entities disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash, without interest.
F2: Represents shares of common stock held directly by BC Perception Holdings, LP ("BC Perception"). Bain Capital Fund XII, L.P. ("Fund XII") is the sole member of BCPE Perception GP, LLC ("Perception GP"), which is the general partner of BC Perception. Bain Capital Investors, LLC ("BCI") is the manager of Bain Capital Partners XII, LLC ("Partners XII" and, together with BCI, BC Perception, Fund XII and Perception GP, the "Bain Capital Entities"), which is the general partner of Fund XII. As a result, each of the Bain Capital Entities may be deemed to share voting and dispositive power with respect to the shares of common stock held by BC Perception. Each of the Bain Capital Entities disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2024 Filed Aug 5, 2024 20:52 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerCommon Stock | 65,679,781 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090909 · ownership.xml · nonDerivative · entry 1 BAIN CAPITAL INVESTORS LLC · CIK 0001040508 · Director · 10% owner BC Perception Holdings, LP · CIK 0001829166 · Director · 10% owner BCPE Perception GP, LLC · CIK 0001829130 · Director · 10% owner Bain Capital Fund XII, LP · CIK 0001706270 · Director · 10% owner Bain Capital Partners XII, LLC · CIK 0001830424 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash, without interest. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash, without interest. F2 · ownership.nature: Represents shares of common stock held directly by BC Perception Holdings, LP ("BC Perception"). Bain Capital Fund XII, L.P. ("Fund XII") is the sole member of BCPE Perception GP, LLC ("Perception GP"), which is the general partner of BC Perception. Bain Capital Investors, LLC ("BCI") is the manager of Bain Capital Partners XII, LLC ("Partners XII" and, together with BCI, BC Perception, Fund XII and Perception GP, the "Bain Capital Entities"), which is the general partner of Fund XII. As a result, each of the Bain Capital Entities may be deemed to share voting and dispositive power with respect to the shares of common stock held by BC Perception. Each of the Bain Capital Entities disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. Read SEC document |
| October 16, 2023 Filed Oct 18, 2023 20:30 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | PurchaseCommon Stock | 5,480,052 | $22.81 | $124,999,986.12 |
DisclosureSEC source: 0000899243-23-019969 · doc4.xml · nonDerivative · entry 1 BAIN CAPITAL INVESTORS LLC · CIK 0001040508 · 10% owner BC Perception Holdings, LP · CIK 0001829166 · 10% owner BCPE Perception GP, LLC · CIK 0001829130 · 10% owner Bain Capital Fund XII, LP · CIK 0001706270 · 10% owner Bain Capital Partners XII, LLC · CIK 0001830424 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 65,679,781 F2 · shares: On October 16, 2023, BC Perception purchased 5,480,052 shares of the Issuer's common stock at a price of $22.81 per share in an underwritten public offering. F1 · ownership.nature: Represents shares of the Issuer's common stock held directly by BC Perception Holdings, LP ("BC Perception"). Bain Capital Fund XII, L.P. ("Fund XII") is the sole member of BCPE Perception GP, LLC ("Perception GP"), which is the general partner of BC Perception. Bain Capital Investors, LLC ("BCI") is the manager of Bain Capital Partners XII, LLC ("Partners XII" and, together with BCI, BC Perception, Fund XII and Perception GP, the "Bain Capital Entities"), which is the general partner of Fund XII. As a result, each of the Bain Capital Entities may be deemed to share voting and dispositive power with respect to the shares of the Issuer's common stock held by BC Perception. Each of the Bain Capital Entities disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. Read SEC document |
| June 07, 2023 Filed Jun 12, 2023 22:05 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | OtherCommon Stock | 432,627 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-015402 · doc4.xml · nonDerivative · entry 1 BAIN CAPITAL INVESTORS LLC · CIK 0001040508 · 10% owner BC Perception Holdings, LP · CIK 0001829166 · 10% owner BCPE Perception GP, LLC · CIK 0001829130 · 10% owner Bain Capital Fund XII, LP · CIK 0001706270 · 10% owner Bain Capital Partners XII, LLC · CIK 0001830424 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 60,199,729 F2 · kind: On June 7, 2023, BC Perception distributed an aggregate of 432,627 shares of the Issuer's common stock (the "Distributed Shares") to certain of its limited partners in a pro-rata in-kind distribution to such limited partners in connection with a redemption of their partnership interests. The Bain Capital Entities did not have a pecuniary interest in any of the Distributed Shares. F1 · ownership.nature: Bain Capital Fund XII, L.P. ("Fund XII") is the sole member of BCPE Perception GP, LLC ("Perception GP"), which is the general partner of BC Perception Holdings, LP ("BC Perception"). Bain Capital Investors, LLC ("BCI") is the manager of Bain Capital Partners XII, LLC ("Partners XII" and, together with BCI, BC Perception, Fund XII and Perception GP, the "Bain Capital Entities"), which is the general partner of Fund XII. As a result, each of the Bain Capital Entities may be deemed to share voting and dispositive power with respect to the shares of the Issuer's common stock held by BC Perception. Each of the Bain Capital Entities disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. Read SEC document |
| November 09, 2020 Filed Nov 12, 2020 22:54 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | PurchaseCommon Stock | 332,293 | $10.30 | $3,422,617.90 |
DisclosureSEC source: 0000899243-20-030861 · doc4.xml · nonDerivative · entry 1 BAIN CAPITAL INVESTORS LLC · CIK 0001040508 · 10% owner BC Perception Holdings, LP · CIK 0001829166 · 10% owner BCPE Perception GP, LLC · CIK 0001829130 · 10% owner Bain Capital Fund XII, LP · CIK 0001706270 · 10% owner Bain Capital Partners XII, LLC · CIK 0001830424 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 60,632,356 F1 · ownership.nature: Bain Capital Fund XII, L.P. ("Fund XII") is the sole member of BCPE Perception GP, LLC ("Perception GP"), which is the general partner of BC Perception Holdings, LP ("BC Perception"). Bain Capital Investors, LLC ("BCI") is the manager of Bain Capital Partners XII, LLC ("Partners XII" and, together with BCI, BC Perception, Fund XII and Perception GP, the "Bain Capital Entities"), which is the general partner of Fund XII. As a result, each of the Bain Capital Entities may be deemed to share voting and dispositive power with respect to the shares of Common Stock held by BC Perception. Each of the Bain Capital Entities disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. Read SEC document |
| October 27, 2020 Filed Oct 30, 2020 00:00 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | PurchaseCommon Stock | 10,000,000 | $10.00 | $100,000,000.00 |
DisclosureSEC source: 0000899243-20-029740 · doc4.xml · nonDerivative · entry 1 BAIN CAPITAL INVESTORS LLC · CIK 0001040508 · 10% owner BC Perception Holdings, LP · CIK 0001829166 · 10% owner BCPE Perception GP, LLC · CIK 0001829130 · 10% owner Bain Capital Fund XII, LP · CIK 0001706270 · 10% owner Bain Capital Partners XII, LLC · CIK 0001830424 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 60,300,063 F1 · kind: On October 27, 2020, BC Perception Holdings, LP ("BC Perception") purchased 10,000,000 shares of the Issuer's Common Stock from the Issuer at a price of $10.00 per share. F2 · ownership.nature: Bain Capital Fund XII, L.P. ("Fund XII") is the sole member of BCPE Perception GP, LLC ("Perception GP"), which is the general partner of BC Perception. Bain Capital Investors, LLC ("BCI") is the manager of Bain Capital Partners XII, LLC ("Partners XII" and, together with BCI, BC Perception, Fund XII and Perception GP, the "Bain Capital Entities"), which is the general partner of Fund XII. As a result, each of the Bain Capital Entities may be deemed to share voting and dispositive power with respect to the shares of Common Stock held by BC Perception. Each of the Bain Capital Entities disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.